Loading
RESPONSE-2 extended ruxolitinib's benefit to PV patients without an enlarged spleen: three times as many reached haematocrit control.
RESPONSE-2 randomised 149 patients with hydroxyurea-resistant or intolerant PV and no palpable spleen to ruxolitinib or best available therapy. Haematocrit control at week 28, the primary endpoint, was achieved by 62 percent on ruxolitinib versus 19 percent on best available therapy (Passamonti and colleagues, Lancet Oncology 2017), with better symptom scores.
Numbers are from the trial as recorded here; see the source links in the table below. This is orientation, not medical advice: ask your team how closely the trial population matches you.
149 enrolled.
| Endpoint | Arm | n | Value | HR (95% CI) | p | Source |
|---|---|---|---|---|---|---|
| Haematocrit control at week 28primary | Ruxolitinib | 74 | 62% | - | - | - |
| Best available therapy | 75 | 19% |
Shares Polycythaemia vera (PV), Ruxolitinib, Novartis, Small-molecule kinase inhibitors and the tags polycythaemia-vera, mpn.
Shares Polycythaemia vera (PV), Ruxolitinib and the tags polycythaemia-vera, mpn.
Shares Polycythaemia vera (PV), Ruxolitinib, Small-molecule kinase inhibitors and the tags polycythaemia-vera, mpn.
Shares Polycythaemia vera (PV), Ruxolitinib and the tags polycythaemia-vera, mpn.
Shares Polycythaemia vera (PV), Ruxolitinib and the tags polycythaemia-vera, mpn.
Shares Polycythaemia vera (PV) and the tags polycythaemia-vera, mpn.
Shares Polycythaemia vera (PV) and the tags polycythaemia-vera, mpn.
Shares Polycythaemia vera (PV) and the tags polycythaemia-vera, mpn.